Synthetic peptide (the amino acid sequence is considered to be commercially sensitive) corresponding to Human E Cadherin.
WB: Human brain lysate;
IHC-P: Human breast carcinoma or cervical carcinoma tissue.
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMab® patents
We are constantly working hard to ensure we provide our customers with best in class antibodies. As a result of this work we are pleased to now offer this antibody in purified format. We are in the process of updating our datasheets. The purified format is designated 'PUR' on our product labels. If you have any questions regarding this update, please contact our Scientific Support team.
Shipped at 4°C. Upon delivery aliquot and store at -20°C. Avoid freeze / thaw cycles.
Cadherins are calcium-dependent cell adhesion proteins. They preferentially interact with themselves in a homophilic manner in connecting cells; cadherins may thus contribute to the sorting of heterogeneous cell types. CDH1 is involved in mechanisms regulating cell-cell adhesions, mobility and proliferation of epithelial cells. Has a potent invasive suppressor role. It is a ligand for integrin alpha-E/beta-7. E-Cad/CTF2 promotes non-amyloidogenic degradation of Abeta precursors. Has a strong inhibitory effect on APP C99 and C83 production.
Non-neural epithelial tissues.
Involvement in disease
Defects in CDH1 are the cause of hereditary diffuse gastric cancer (HDGC) [MIM:137215]. An autosomal dominant cancer predisposition syndrome with increased susceptibility to diffuse gastric cancer. Diffuse gastric cancer is a malignant disease characterized by poorly differentiated infiltrating lesions resulting in thickening of the stomach. Malignant tumors start in the stomach, can spread to the esophagus or the small intestine, and can extend through the stomach wall to nearby lymph nodes and organs. It also can metastasize to other parts of the body. Note=Heterozygous germline mutations CDH1 are responsible for familial cases of diffuse gastric cancer. Somatic mutations in the has also been found in patients with sporadic diffuse gastric cancer and lobular breast cancer. Defects in CDH1 are a cause of susceptibility to endometrial cancer (ENDMC) [MIM:608089]. Defects in CDH1 are a cause of susceptibility to ovarian cancer (OC) [MIM:167000]. Ovarian cancer common malignancy originating from ovarian tissue. Although many histologic types of ovarian neoplasms have been described, epithelial ovarian carcinoma is the most common form. Ovarian cancers are often asymptomatic and the recognized signs and symptoms, even of late-stage disease, are vague. Consequently, most patients are diagnosed with advanced disease.
Contains 5 cadherin domains.
During apoptosis or with calcium influx, cleaved by a membrane-bound metalloproteinase (ADAM10), PS1/gamma-secretase and caspase-3 to produce fragments of about 38 kDa (E-CAD/CTF1), 33 kDa (E-CAD/CTF2) and 29 kDa (E-CAD/CTF3), respectively. Processing by the metalloproteinase, induced by calcium influx, causes disruption of cell-cell adhesion and the subsequent release of beta-catenin into the cytoplasm. The residual membrane-tethered cleavage product is rapidly degraded via an intracellular proteolytic pathway. Cleavage by caspase-3 releases the cytoplasmic tail resulting in disintegration of the actin microfilament system. The gamma-secretase-mediated cleavage promotes disassembly of adherens junctions.
Cell junction. Cell membrane. Endosome. Golgi apparatus > trans-Golgi network. Colocalizes with DLGAP5 at sites of cell-cell contact in intestinal epithelial cells. Anchored to actin microfilaments through association with alpha-, beta- and gamma-catenin. Sequential proteolysis induced by apoptosis or calcium influx, results in translocation from sites of cell-cell contact to the cytoplasm. Colocalizes with RAB11A endosomes during its transport from the Golgi apparatus to the plasma membrane.
Immunohistochemical staining of paraffin embedded human skin with purified ab76319 at a working dilution of 1 in 100. The secondary antibody used is a HRP polymer for rabbit IgG. The sample is counter-stained with hematoxylin. Antigen retrieval was perfomed using Tris-EDTA buffer, pH 9.0. PBS was used instead of the primary antibody as the negative control, and is shown in the inset.
ab76319 (purified) at 1/50 immunoprecipitating E cadherin in human fetal brain (Lane 1). For western blotting, a HRP-conjugated anti-rabbit IgG was used as the secondary antibody (1/1000).
Blocking buffer and concentration: 5% NFDM/TBST.
Diluting buffer and concentration: 5% NFDM /TBST.
Western blot - Anti-E Cadherin (phospho S838 + S840) antibody [EP913(2)Y] (ab76319)
All lanes : Anti-E Cadherin (phospho S838 + S840) antibody [EP913(2)Y] (ab76319) at 1/1000000 dilution (unpurified)
Lane 1 : Human brain lysate, untreated Lane 2 : Human brain lysate treated with AP
Lysates/proteins at 10 µg per lane.
Secondary All lanes : Goat anti-rabbit HRP at 1/1000 dilution
Predicted band size: 97 kDa
Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-E Cadherin (phospho S838 + S840) antibody [EP913(2)Y] (ab76319)This image is courtesy of an anonymous Abreview
Unpurified ab76319 staining E Cadherin in mouse skin (pilosebaceous untis) tissue sections by Immunohistochemistry (IHC-P - paraformaldehyde-fixed, paraffin-embedded sections). Tissue was fixed with paraformaldehyde, permeabilized with Tween-20 and blocked with 10% normal donkey serum + 1% serum for 40 minutes at room temperature; antigen retrieval was by heat mediation in a citrate buffer, pH 6. Samples were incubated with primary antibody (1/400 in 1% BSA) for 16 hours at 4°C. An Alexa Fluor® 488-conjugated donkey anti-rabbit IgG polyclonal (1/400) was used as the secondary antibody.
Qiao B et al. MicroRNA-27a-3p Modulates the Wnt/ß-Catenin Signaling Pathway to Promote Epithelial-Mesenchymal Transition in Oral Squamous Carcinoma Stem Cells by Targeting SFRP1. Sci Rep7:44688 (2017).
Read more (PubMed: 28425477) »
Hou T et al. CLCA4 inhibits bladder cancer cell proliferation, migration, and invasion by suppressing the PI3K/AKT pathway. Oncotarget8:93001-93013 (2017).
Read more (PubMed: 29190973) »